GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.87
0.09 (5.06%)
▲
5d:
-4.59%
30d:
-6.97%
90d:
-19.74%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GRI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: GRI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.87, which is considered slightly low relative to its 30-day fair value range of $1.87 to $2.21.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1023.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1023.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.87 -
$2.21
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 1023.0% below Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$1.87 -
$2.21
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.31
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.74
Wall Street Target
$21.00
(+1023.0%)
Share & Embed Analysis
Last updated: July 02, 2026 10:41 PM ET
Data refreshes hourly during market hours. Next update: 11:41 PM
Data refreshes hourly during market hours. Next update: 11:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
